Hot off the press from the RTI: Ex vivo machine perfusion enables robust and widespread lipophilic-conjugated siRNA delivery to the porcine lung
buff.ly/XcevKPc #RNA #RNATherapeutics

Hot off the press from the RTI: Ex vivo machine perfusion enables robust and widespread lipophilic-conjugated siRNA delivery to the porcine lung
buff.ly/XcevKPc #RNA #RNATherapeutics
TransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
TransCode Therapeutics (NASDAQ: RNAZ) expands its global patent portfolio with new IP grants in Australia and Japan covering RNA-based nanoparticle therapies targeting multiple cancers, including breast, lung, and pancreatic. #Oncology #RNATherapeutics
Hot off the press from the RTI: Nucleic acid therapeutics in neurodegenerative disorders: emerging technologies and clinical landscape
buff.ly/qJUGYVq #RNA #RNATherapeutics
Hot off the press from the RTI: Population genetics, trait mapping and fungal pathogen surveillance using untargeted sequencing in timber rattlesnakes (Crotalus horridus)
buff.ly/mbA1ICW #RNA #RNATherapeutics
Welcome Microsynth โ The Swiss DNA Company โ as our first Booth Sponsor for RNATX 2027!
Join us on 28 January 2027 in Bern.
Register: www.conftool.net/chrnat2027
More info: rnatx.ch
Hot off the press from the Watts & Khvorova labs: Albumin-binding dendrimer-conjugated siRNA enables safe and effective gene silencing throughout the central nervous system buff.ly/FUvJ0hf
#RNA #RNATherapeutics
โฐ The deadline is TODAY!
Register for OTDC 2027 and connect with advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
๐
May 11โ12, 2027 | Boston + Hybrid
๐ oligo-nucleotide.com
From molecular insights to life-changing therapies ๐งฌ
OTDC 2027 brings together emerging advances in Oligonucleotide Therapeutics, RNA Technologies, Drug Delivery, CRISPR & Aptamer Technologies.
๐
May 11โ12, 2027
๐ Boston | Hybrid
๐ oligo-nucleotide.com
At #DrugDiscoveryOnTarget, our CSO, Dominic Reynolds, will highlight REM-422, our first-in-class mRNA degrader targeting the MYB oncogene, and discuss how our REMasterยฎ platform is enabling new approaches to previously undruggable RNA targets.
TODAY at 11 AM CDT: Molecular Therapy Presents - AI-Powered Precision Medicine: From Biomarker Discovery to Therapeutic Design and Delivery
Join us for this exciting FREE webinar today: http://dlvr.it/TVcMM4
#ArtificialIntelligence #GeneTherapy #RNAtherapeutics #ASGCT
๐งฌ From Nucleic Acids to Real-World Impact.
OTDC 2027 explores advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies.
๐
May 11โ12, 2027 | ๐ Boston, MA & Virtual
๐ oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery
๐งฌ Small molecules. Big possibilities.
OTDC 2027 explores emerging advances in oligonucleotide therapeutics, RNA medicines, and innovative delivery technologies.
๐
May 11โ12, 2027 | ๐ Boston, MA | ๐ Hybrid
๐ oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #DrugDelivery #RNAMedicine
๐งฌ Molecular frontiers. Therapeutic possibilities.
OTDC 2027 explores new directions in oligonucleotide therapeutics, RNA medicines, and delivery science.
๐
May 11โ12, 2027 | Boston, MA & Virtual
๐ oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics
๐งฌ OTDC 2027 โ Exploring the scientific frontiers of oligonucleotide therapeutics, RNA medicines, and advanced delivery technologies.
๐
May 11โ12, 2027 | Boston, MA & Virtual
๐ oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics
From molecular innovation to therapeutic possibilities. ๐งฌ
OTDC 2027 highlights evolving research in oligonucleotide therapeutics, RNA & mRNA, and next-generation delivery technologies.
May 11โ12, 2027 | Boston, MA & Virtual
oligo-nucleotide.com
Smaller molecules. Bigger possibilities.
Explore the evolving science of oligonucleotide therapeutics, RNA & mRNA, and next-generation delivery at OTDC 2027.
May 11โ12, 2027 | Boston, MA & Virtual
oligo-nucleotide.com
From nucleic acids to real-world impact.
OTDC 2027 explores advances in oligonucleotide therapeutics, RNA medicines, and delivery technologies.
๐
May 11โ12, 2027
๐ Boston, MA & Virtual
๐ oligo-nucleotide.com
๐งฌ OTDC 2027
โGreat medicines begin with precise molecules.โ
Explore advances in oligonucleotide therapeutics, RNA medicines & targeted delivery.
๐
May 11โ12, 2027 | ๐ Boston, MA | Hybrid
๐ oligo-nucleotide.com
๐งฌ Discover the evolving landscape of oligonucleotide therapeutics, RNA medicines, and next-generation delivery technologies at OTDC 2027.
๐
May 11โ12, 2027
๐ Boston, Massachusetts, USA | Hybrid
๐ oligo-nucleotide.com
#OTDC2027 #Oligonucleotides #RNATherapeutics #mRNA #DrugDelivery #RNAResearch